EP0791592A2 — Azetidines
Assigned to Pfizer Ltd Great Britain · Expires 1997-08-27 · 29y expired
What this patent protects
The present invention provides compounds of the formula (I):- and the pharmaceutically acceptable salts thereof, wherein R is C 3 -C 7 cycloalkyl, aryl or C 1 -C 6 alkyl, said C 1 -C 6 alkyl being optionally substituted by fluoro, -COOH, -COO(C 1 -C 4 ) alkyl, C 3 -C…
USPTO Abstract
The present invention provides compounds of the formula (I):- and the pharmaceutically acceptable salts thereof, wherein R is C 3 -C 7 cycloalkyl, aryl or C 1 -C 6 alkyl, said C 1 -C 6 alkyl being optionally substituted by fluoro, -COOH, -COO(C 1 -C 4 ) alkyl, C 3 -C 7 cycloalkyl, adamantyl, aryl or het 1 , and said C 3 -C 7 cycloalkyl being optionally substituted by 1 or 2 substituents each independently selected from C 1 -C 4 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkoxy, hydroxy, fluoro, fluoro(C 1 -C 4 ) alkyl and fluoro(C 1 -C 4 )alkoxy; R 1 is phenyl, benzyl, naphthyl, thienyl, benzothienyl or indolyl, each optionally substituted by 1 or 2 substituents each independently selected from C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo and trifluoromethyl; R 2 represents various groups; X is C 1 -C 4 alkylene; and X 1 is a direct link or C 1 -C 6 alkylene. Such compounds and salts are useful as tachykinin antagonists.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.